How to Use Templates and Style Guides for Investigator Brochure (IB) Creation

Creating an effective Investigator’s Brochure (IB) is essential in communicating clinical and nonclinical data about an investigational product (IP) to investigators. A well-structured IB not only supports ethical decision-making but also meets global regulatory expectations. This article outlines how to use templates and style guides to streamline IB creation while ensuring compliance, clarity, and consistency across clinical trials.

By following this tutorial, medical writers, clinical professionals, and QA personnel can adopt best practices in documentation and avoid unnecessary delays in clinical development.

Why Standardized IB Templates Matter:

Templates ensure uniformity in content structure, which facilitates easier review, comparison, and regulatory submission. Benefits include:

• Consistency across product documents and development programs
• Reduced errors in content formatting
• Streamlined reviews from sponsors and ethics committees
• Faster adaptation during updates or protocol amendments

Regulatory agencies such as EMA and CDSCO encourage the use of consistent formatting in clinical documentation including the IB.

IB Template Components: Standard Structure

Most investigator brochures follow a structure aligned with ICH E6(R2) and the Common Technical Document (CTD) format. A typical IB template includes:

1. Title Page: Product name, sponsor, IB version, date
2. Confidentiality Statement
3. Table of Contents
4. Summary: Nonclinical and clinical overview
5. Introduction: Investigational product rationale
6. Physical, Chemical, and Pharmaceutical Properties
7. Nonclinical Studies: Animal toxicity, pharmacology
8. Effects in Humans: Phase I–III data, adverse events
9. Summary of Data and Guidance for Investigator Use
10. References and Appendices

Standard templates can be sourced from Pharma SOP templates or company-specific document management systems. Each section should contain headings, numbering, and footers with version control for compliance tracking.

Using Style Guides in IB Creation:

A style guide standardizes how content is written and presented. It goes beyond layout and formatting—it ensures clarity and consistency in tone, grammar, terminology, and citation format. Key elements include:

• Font and Size: e.g., Arial 11pt, 1.15 spacing
• Numbering Scheme: 1.0, 1.1, 1.1.1 for sections
• Writing Tone: Active voice, concise and objective language
• Tables and Figures: Numbered and captioned correctly
• Abbreviations: Defined on first use and listed in a glossary
• Citations: Standardized reference style, e.g., AMA or Vancouver

Many organizations use internal documentation style guides or follow industry-recognized standards like the AMA Manual of Style.

IB Authoring Best Practices:

Here’s how to approach IB writing using templates and style guides:

1. Start with a verified template: Use sponsor-approved or CTD-based IB templates to ensure inclusion of all required sections.
2. Adopt a modular writing approach: Assign sections to experts (e.g., nonclinical to toxicologists, clinical to medical writers).
3. Incorporate peer-reviewed content: Pull from validated sources like CSR data, clinical trial protocols, and stability studies.
4. Use version-controlled document editing tools: MS Word with Track Changes, or systems like Veeva Vault and MasterControl.
5. Schedule iterative reviews: Include stakeholders from regulatory, medical, and clinical operations.

Templates should have embedded instructions (hidden text or comments) to guide new writers on content expectations for each section.

Ensuring Compliance with Regulatory and Sponsor Requirements:

Templates and style guides help meet the expectations set by regulatory bodies and sponsors. To ensure compliance:

• Follow GMP documentation practices for accurate data inclusion
• Use standard terms consistent with pharma regulatory compliance guidelines
• Include required disclaimers and confidentiality statements
• Track version control via a document history table
• Ensure accurate reference of study reports and literature

Noncompliance in structure or missing mandatory elements can delay ethics committee approvals or result in feedback from regulators like TGA (Australia).

Tools and Platforms That Support IB Template Use:

There are several tools that aid in enforcing consistency and reuse of IB components:

• Veeva Vault RIM: Centralized document templates with approval workflows
• Microsoft Word Templates: With macro-enabled headers and section formatting
• Medidata and TrialMaster: Integration with TMF for version tracking
• Custom SOP platforms: Manage templates for pharma validation and IB content consistency

Using these systems ensures traceability, audit-readiness, and quicker updates to IBs throughout product lifecycle changes.

Checklist for Finalizing IB Templates:

Before releasing the IB, conduct a template and formatting review using this checklist:

• Title page includes product name, version, sponsor details
• Confidentiality statement and legal notices included
• All sections per ICH guideline are present
• Consistent fonts, spacing, and numbering
• Figures and tables are labeled and referenced
• All references are cited and formatted correctly
• Document properties and version history are updated
• Language is professional, clear, and non-promotional

This final QA review is often supported by cross-functional teams, including QA, Regulatory Affairs, and Medical Affairs.

Conclusion:

The use of templates and style guides in IB development is not just a formatting convenience—it’s a strategic advantage in ensuring regulatory acceptance, communication efficiency, and investigator clarity. By embedding quality early in the document creation process, organizations can streamline future updates and maintain audit-ready documentation at all times.

Adopt standardized practices now, and your IBs will stand strong through scrutiny—from IRBs to international regulatory agencies.